Setmelanotide
RM-493-033
Phase 3 small_molecule completed
Quick answer
Setmelanotide for Bardet-Biedl Syndrome is a Phase 3 program (small_molecule) at Rhythm Pharmaceuticals Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Rhythm Pharmaceuticals Netherlands B.V.
- Indication
- Bardet-Biedl Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed